Pliant Therapeutics, Inc. financial data

Symbol
PLRX on Nasdaq
Industry
Pharmaceutical Preparations
Location
331 Oyster Point Boulevard, South San Francisco, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 3, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.27K % -37.1%
Debt-to-equity 24.9 % +235%
Return On Equity -56.8 % -82.5%
Return On Assets -45.5 % -57%
Operating Margin -78.4K % -5328%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 61.2M shares +1.51%
Common Stock, Shares, Outstanding 60.9M shares +1.57%
Entity Public Float 608M USD -39.7%
Common Stock, Value, Issued 6K USD 0%
Weighted Average Number of Shares Outstanding, Basic 60.5M shares +3.1%
Weighted Average Number of Shares Outstanding, Diluted 60.5M shares +3.1%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
Research and Development Expense 169M USD +32.5%
General and Administrative Expense 59.1M USD +1.95%
Operating Income (Loss) -228M USD -24%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -210M USD -30.4%
Earnings Per Share, Basic -3.47 USD/shares -26.2%
Earnings Per Share, Diluted -3.47 USD/shares -26.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 71.2M USD +12.6%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD -100%
Assets, Current 362M USD -28.3%
Property, Plant and Equipment, Net 5.53M USD +54.9%
Operating Lease, Right-of-Use Asset 27.2M USD +2150%
Other Assets, Noncurrent 435K USD +11%
Assets 397M USD -22.5%
Accounts Payable, Current 5.96M USD +31.5%
Employee-related Liabilities, Current 11.2M USD +23.4%
Accrued Liabilities, Current 12.4M USD +20.9%
Liabilities, Current 33.2M USD +16.5%
Operating Lease, Liability, Noncurrent 29.4M USD
Liabilities 92.9M USD +141%
Accumulated Other Comprehensive Income (Loss), Net of Tax 321K USD -6.96%
Retained Earnings (Accumulated Deficit) -710M USD -42.1%
Stockholders' Equity Attributable to Parent 304M USD -35.8%
Liabilities and Equity 397M USD -22.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -30.3M USD +0.02%
Net Cash Provided by (Used in) Financing Activities 21.8M USD -92%
Net Cash Provided by (Used in) Investing Activities 59.5M USD
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 60.9M shares +1.57%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 51.1M USD -25.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 72.7M USD +12.3%
Interest Paid, Excluding Capitalized Interest, Operating Activities 501K USD +77.7%
Deferred Tax Assets, Valuation Allowance 198M USD +28.9%
Deferred Tax Assets, Gross 205M USD +32%
Operating Lease, Liability 30M USD
Depreciation 2.13M USD +15.4%
Payments to Acquire Property, Plant, and Equipment 1.49M USD +815%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -210M USD -32.3%
Lessee, Operating Lease, Liability, to be Paid 41.9M USD +2930%
Property, Plant and Equipment, Gross 16.3M USD +33.3%
Operating Lease, Liability, Current 542K USD -58.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 4.41M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 3.29M USD +138%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure -29.4%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 11.9M USD +18494%
Lessee, Operating Lease, Liability, to be Paid, Year Three 5.9M USD
Deferred Tax Assets, Operating Loss Carryforwards 94.9M USD +20.9%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 10.2M USD +28.4%
Lessee, Operating Lease, Liability, to be Paid, Year Four 7.47M USD
Operating Lease, Payments 800K USD +33.3%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 37.6M USD -15.4%
Interest Expense 1.4M USD +27.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%